Homocysteine and Heart Disease

Why this comes up at all

Homocysteine is one of the most instructive stories in modern preventive medicine, and it is instructive precisely because it did not work out.

The setup was close to ideal. Observational studies consistently found that people with higher homocysteine had more cardiovascular disease. The mechanism was plausible, with proposed effects on the vessel lining and on clotting. And the intervention was cheap, safe and widely available, since B6, B9 and B12 reliably lower homocysteine.

Everything about it said this should work. So a generation of large randomized trials went out to find out.

The reason this brief exists is that the answer they came back with is still not widely known, and homocysteine is still sold in some quarters as a cardiovascular lever to pull.

It also happens to be one of the clearest available demonstrations of why association and causation are different things, which is worth having in your head for every other claim on this site.

What the human evidence actually shows

The 2017 Cochrane review is the reference point, and it is the third update of a review first published in 2009.

It searched CENTRAL, MEDLINE, Embase, LILACS and Web of Science, included randomized controlled trials with at least one year of follow-up, and used myocardial infarction and stroke as primary outcomes. It identified 15 randomized controlled trials with 71,422 participants, with 9 of the 15 at low risk of bias and follow-up from one to 7.3 years.

On myocardial infarction: 7.1 percent on homocysteine-lowering treatment versus 6.0 percent on placebo, relative risk 1.02, I-squared 0 percent, across 12 trials and 46,699 people. High-quality evidence. No benefit.

On death from any cause: 11.7 percent versus 12.3 percent, relative risk 1.01, across 11 trials and 44,817 people. High-quality evidence. No benefit.

On serious adverse events: 8.3 percent versus 8.5 percent. High-quality evidence.

Then the one positive finding, and it deserves reporting as carefully as the negatives. Stroke came out lower on treatment: 4.3 percent versus 5.1 percent, relative risk 0.90, across 10 trials and 44,224 people. Also high-quality evidence.

The review found no evidence of publication bias, and trial sequential analyses were performed.

So the summary is precise rather than sweeping. Lowering homocysteine with B vitamins does not reduce heart attacks or all-cause mortality, on high-quality evidence at scale. It produces a small reduction in stroke.

What this means in practice

The first consequence is to stop treating a homocysteine number as a cardiovascular target. The trials that would have shown that were run properly, at scale, and they did not show it.

The second consequence is more interesting, and it is why homocysteine is still worth measuring.

The trials answered a question about treatment, not a question about diagnosis. They gave B vitamins to large mixed populations, most of whom were not deficient, and asked whether events fell. That is a completely different question from measuring homocysteine in one person to find out whether their methylation pathway has the cofactors it needs.

Homocysteine is cleared by pathways requiring B12, folate and B6. A raised level is a functional signal that one of those is short, and that is genuinely useful information that a serum B12 alone can miss.

So the marker survives the trials with its diagnostic use intact and its therapeutic framing removed. That is a narrower role and a real one.

There is a practical warning attached. A 2024 review in Food and Nutrition Bulletin worked through evidence that excess folic acid can exacerbate and mask B12 deficiency, reporting lower cognitive scores and higher homocysteine and methylmalonic acid in people with low B12 and elevated folate. So reaching for a high-dose B complex because a number looked high is exactly the wrong move.

If cardiovascular risk is the actual question, apoB has considerably better evidence behind it. A 2025 systematic review of 15 discordance studies covering 593,354 participants found apoB outperformed LDL cholesterol in 9 of 9 comparisons.

The honest hedge

I am not a doctor and I am not diagnosing anyone.

I want to hold two things together here without letting either collapse the other. Raised homocysteine is genuinely useful information about B vitamin status. It is not a number to treat for its own sake.

The stroke finding is real and I have reported it rather than burying it, because reporting only the negative results would be its own dishonesty. It is also small, and it does not resurrect the broader cardiovascular claim.

The specific caution that matters: test B12 and folate before correcting anything, because high-dose folic acid can correct the blood picture of B12 deficiency while neurological damage continues underneath, and that damage does not always reverse.

A markedly raised homocysteine also deserves kidney function checked, since reduced kidney function is one of the strongest non-nutritional drivers. That is a doctor conversation.

And the broader lesson is worth carrying beyond this page. A strong association, a plausible mechanism and a safe cheap intervention still were not enough. That should make everyone, including me, more careful about the next compelling story.

What to do with this

Stop treating homocysteine as a heart attack lever. Fifteen randomized trials in 71,422 people found no benefit for myocardial infarction or all-cause mortality, at high-quality evidence.

Keep it as a functional B vitamin marker. That use survives the trials intact, and a serum B12 alone can miss what it shows.

Never correct folate without checking B12 first. High-dose folic acid can mask B12 deficiency while neurological damage continues, and that is the specific harm to avoid.

Test both together. A B12 and folate panel runs them from one draw.

Take a markedly raised result to a doctor. Reduced kidney function is a strong driver and it is not something to work around.

If cardiovascular risk is the question, measure the marker with the evidence. ApoB on an advanced lipid panel.

Carry the general lesson. Association plus plausible mechanism plus safe intervention still was not enough here, and that should sharpen your reading of every similar claim.

Where the paid report goes further

This page covers what the published evidence says in general. It cannot tell you what it means for you, because it does not know your medications, your labs, your history, or your dose.

A paid research report does that work. Jess builds it around your actual situation, walks the citations, and writes what the evidence supports for someone in your position. The brief is the shorter version. The deep dive is the one where every citation is read and the reasoning is laid out end to end, and Jess reviews every deep dive personally before it goes out.

Neither is medical advice, and neither replaces your prescriber. What they replace is the evening you would otherwise spend trying to work out which of forty search results is telling you the truth.